Similarly for CRC, one investigation of the effect of KRAS mutations on 2-[18F]FDG uptake of CRC lesions found no correlation [23], while others found statistically significant correlations for primary tumors [13, 24–26]. The gene discussed is KRAS; the disease is colorectal carcinoma.